NXT USA’s shatavari extract boosts women’s ovarian function, metabolism and hormonal balance
Key takeaways
- Xeya Modern Shatavari improves ovarian morphology in women with PCOS by reducing cyst size, follicle count, and overall ovarian volume.
- Clinical results show significant hormonal improvements, including reduced testosterone levels and better insulin sensitivity.
- Supplementation also leads to visible physical benefits, such as clearer skin, reduced unwanted hair growth, and more regular menstrual cycles.
New clinical findings support that NXT USA’s shatavari extract, Xeya Modern Shatavari, supports ovarian function, metabolic health, and hormone balance in women with Polycystic Ovary Syndrome (PCOS).
The standardized extract, positioned toward the diversifying women’s hormonal health market, “significantly improved” ovarian morphology and androgen-related symptoms while supporting hormonal balance and insulin sensitivity in women of 20–35 years old.
The study published in Food & Nutrition Research detailed these positive changes manifesting through improvements in skin, hair, and menstrual patterns of perimenopausal women.
Moreover, Xeya Modern Shatavari was well-tolerated among participants, with no serious adverse events reported.
“Many women don’t realize how deeply hormonal imbalance can influence reproductive health, metabolism, and skin,” says Eric Anderson, managing director of NXT USA. “Xeya Modern Shatavari supports natural hormone balance, helping promote healthy ovarian function, consistent cycles, and hormonal markers tied to clear skin and metabolic resilience.”
Hormonal balance and metabolic support
The randomized, double‑blind, placebo‑controlled clinical trial supporting Xeya Modern Shatavari involved 60 women with PCOS for 84 days.
Key outcomes from the 12-week trial included improvements in polycystic ovarian morphology after daily supplementation with 100 mg of the botanical extract. Women taking the extract experienced a 21% reduction in ovarian volume, a 41% reduction in cyst size, and a 20–25% reduction in follicle count.
Key outcomes from the 12-week trial included improvements in polycystic ovarian morphology after daily supplementation with 100 mg of the botanical extract.In terms of hormonal balance, women supplementing saw a 33.9% reduction in total testosterone, a 31.8% increase in Sex Hormone-Binding Globulin, and an 18.6% improvement in the Luteinizing Hormone: Follicle-Stimulating Hormone ratio.
For metabolic support, this group experienced a 14% improvement in insulin sensitivity alongside visible physical improvements. These included a 44% reduction in acne severity, a 46% reduction in hirsutism, and reductions in waist and hip circumference.
Meanwhile, the women reported better menstrual cycle regularity over baseline.
“More than symptom cover-up”
NXT USA highlights that supplement brands addressing PCOS are under pressure to “deliver more than symptom cover-up.” It notes clinicians and consumers are more actively seeking plant-based, clinically validated solutions that jointly address ovarian health, hormones, and metabolism.
“With an additional peer-reviewed study already published on perimenopause, Xeya is clinically validated in two distinct phases of women’s health — and at a fraction of the dose used by competing ingredients,” details the company.
The supplier notes that the low-dose ingredient offers lower cost-per-serving across capsules, gummies, powders, beverages, and ready-to-eat formats, while highlighting opportunities in skin/hair/hormone “PCOS beauty-from-within” concepts.
“This approach provides a degree of validation unmatched among shatavari suppliers,” says Anderson. “This framework turns good studies into great ones and good claims into claims that can build a supplement brand. This approach is exactly why brands — big brands — choose to partner with us.”
NXT USA produces Xeya through a fully traceable supply chain. The shatavari is wildcrafted under regulated forest management, peeled and dried by local women’s cooperatives, and processed using only purified water and organic ethanol.
Final extraction and manufacturing follow low-carbon, contaminant-free practices and carry globally recognized certifications.
In other published clinical findings, a recent study supported NXT USA’s claims that its patent-pending herbal blend, BluNADBooster, outperforms a popular NAD+ precursor, nicotinamide riboside, in raising NAD+ levels — a marker of longevity.
Meanwhile, the company received independent third-party testing last November to back the claims of its patented blend of tender okra pods (Abelmoschus esculentus) and ashwagandha (Withania somnifera), Digexin, designed to support digestive health. This enables ingredient claims for finished products in accordance with the supplement’s recommended use in the US.
